Bicyclo Ring System Having The Oxazine Ring As One Of The Cyclos (e.g., Benzoxazines, Etc.) Patents (Class 544/105)
  • Patent number: 10815251
    Abstract: The present invention relates to a method for the manufacture of 2-(3-(alkyl or alkenyl)morpholino)-ethan-1-ols by reduction of 8a-(alkyl or alkenyl)hexahydrooxazolo[2,3-c][1,4]oxazines encompassing a process for producing 2-(3-(4-propylheptyl)morpholino)ethan-1-ol with the INN name delmopinol. The invention also relates to 1-chloro-4-propylhept-3-ene, 1-iodo-4-propylhept-3-ene, 8a-(4-propylheptyl)hexahydrooxazolo[2,3-c][1,4]oxazine, 8a-(4-propylhept-3-en-1-yl)hexahydrooxazolo[2,3-c][1,4]oxazine and 2-(3-(4-propylhept-3-en-1-yl)morpholino)ethan-1-ol which are intermediates in the delmopinol process.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: October 27, 2020
    Assignee: Lundbeck Pharmaceuticals Italy S.P.A.
    Inventors: Carla De Faveri, Mariano Stivanello
  • Patent number: 10800748
    Abstract: The present invention provides an improved process for the manufacture (R)-6-hydroxy-8-[1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethyl-ethylamino-ethyl]-2H-1,4-benzoxazin-3(4H)-one, in high purity and high yield, through the use of 1,1-dimethyl-2-(4-methoxyphenyl)ethyl amine L-tartrate salt, 1,1-dimethyl-2-(4-methoxyphenyl)ethyl amine maletate salt or the camphorsulfonate salt of intermediate (4). The invention also relates to said salts, to processes for preparing them and to their use for the manufacture of (R)-6-hydroxy-8-[1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethyl-ethylamino-ethyl]-2H-1,4-benzoxazin-3(4H)-one or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: October 13, 2020
    Assignee: INKE, S.A.
    Inventors: Enric Capdevila Urbaneja, Juan Huguet Clotet, Pere Dalmases Barjoan
  • Patent number: 10781209
    Abstract: The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: September 22, 2020
    Assignee: Incyte Corporation
    Inventors: Andrew P. Combs, Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh
  • Patent number: 10745397
    Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof has an EP4 receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of EP4 receptor associated diseases (e.g., rheumatoid arthritis, aortic aneurysm (e.g. abdominal aortic aneurysm, thoracic aortic aneurysm, thoracoabdominal aortic aneurysm etc.), endometriosis, ankylosing spondylitis, inflammatory breast cancer etc.) and the like.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: August 18, 2020
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Dinesh Barawkar, Anil M Deshpande, Santosh Patil, Yogesh Waman, Anil Panmand, Dilip Jadhav, Bheemashankar Kulkarni
  • Patent number: 10717747
    Abstract: The present invention relates to a method for the manufacture of 2-(3-(alkyl or alkenyl)morpholino)-ethan-1-ols by reduction of 8a-(alkyl and alkenyl)hexahydrooxazolo[2,3-c][1,4]oxazines encompassing a process for producing 2-(3-(4-propylheptyl)morpholino)ethan-1-ol with the INN name delmopinol. The invention also relates to 1-chloro-4-propylhept-3-ene, 1-iodo-4-propylhept-3-ene, 8a-(4-5 propylheptyl)hexahydrooxazolo[2,3-c][1,4]oxazine, 8a-(4-propylhept-3-en-1-yl)hexahydrooxazolo[2,3-c][1,4]oxazine and 2-(3-(4-propylhept-3-en-1-yl)morpholino)ethan-1-ol which are intermediates in the delmopinol process.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: July 21, 2020
    Assignee: Lundbeck Pharmaceuticals Italy S.P.A.
    Inventors: Carla De Faveri, Mariano Stivanello
  • Patent number: 10703719
    Abstract: A method for producing (2S,5S)/(2R,5R)-5-hydroxypiperidine-2-carboxylic acid represented by the formula (10) below: the method including removing the protecting group from the hydroxyl group in a compound represented by formula (7) below: (wherein P represents a protecting group, R3 represents an alkyl group containing 1 to 4 carbon atoms, and A represents an alkyl group containing 1 to 10 carbon atoms, an aryl group containing 6 to 12 carbon atoms, an alkyloxy group containing 1 to 4 carbon atoms, or an aralkyloxy group containing 7 to 20 carbon atoms) to synthesize a compound represented by formula (8) below: (wherein R3 represents an alkyl group containing 1 to 4 carbon atoms, and A represents an alkyl group containing 1 to 10 carbon atoms, an aryl group containing 6 to 12 carbon atoms, an alkyloxy group containing 1 to 4 carbon atoms, or an aralkyloxy group containing 7 to 20 carbon atoms).
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: July 7, 2020
    Assignee: API CORPORATION
    Inventors: Jun Takehara, Masato Murai, Takashi Ohtani, Tomoko Maeda, Tsugihiko Hidaka
  • Patent number: 10611741
    Abstract: The present invention relates to substituted benzoxazines and related compounds and derivatives thereof and/or pharmaceutically acceptable salts, compositions, and methods of uses thereof.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: April 7, 2020
    Assignee: THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE
    Inventors: Andrey S. Tsvetkov, Steven M. Finkbeiner, Michael A. Pleiss, Robert Greenhouse
  • Patent number: 10472331
    Abstract: The present invention relates to a novel crystal form of the monosodium salt of foramsulfuron, a method for preparing this crystal form, use thereof in agrochemical formulations and also particular compositions, mixtures or agrochemical formulations comprising this crystal form, and also a novel monomethanol solvate of the monosodium salt of foramsulfuron.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: November 12, 2019
    Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFT
    Inventors: Stefan Antons, Britta Olenik, Martin Krueger
  • Patent number: 10472358
    Abstract: The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: November 12, 2019
    Assignee: Incyte Corporation
    Inventors: Andrew P. Combs, Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh
  • Patent number: 10464937
    Abstract: The present invention relates to processes for the preparation of N-protected (2S,5R)-6-hydroxy-7-oxo-N-piperidin-4-yl-1,6-diazabicyclo[3.2.1]octane-2-carboxamide intermediates. Such compounds have application in the preparation of beta-lactamase inhibitors such as 7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamides and esters, in particular, the beta lactamase inhibitor, (2S,5R)-7-oxo-N-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide. The present invention also encompasses intermediates useful in the disclosed processes and methods for their preparation.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: November 5, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jianguo Yin, Zhijian Liu, Nobuyoshi Yasuda, Mark Weisel
  • Patent number: 10428056
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: October 1, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masataka Murakami, Jinichi Yonemori, Takuto Kojima
  • Patent number: 10370330
    Abstract: A method for producing (2S,5S)/(2R,5R)-5-hydroxypiperidine-2-carboxylic acid represented by the formula (10) below: the method comprising the step of removing the protecting group from the hydroxyl group in a compound represented by the formula (7) below: (wherein P represents a protecting group, R3 represents an alkyl group containing 1 to 4 carbon atoms, and A represents an alkyl group containing 1 to 10 carbon atoms, an aryl group containing 6 to 12 carbon atoms, an alkyloxy group containing 1 to 4 carbon atoms, or an aralkyloxy group containing 7 to 20 carbon atoms) to synthesize a compound represented by the formula (8) below: (wherein R3 represents an alkyl group containing 1 to 4 carbon atoms, and A represents an alkyl group containing 1 to 10 carbon atoms, an aryl group containing 6 to 12 carbon atoms, an alkyloxy group containing 1 to 4 carbon atoms, or an aralkyloxy group containing 7 to 20 carbon atoms).
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: August 6, 2019
    Assignee: API CORPORATION
    Inventors: Jun Takehara, Masato Murai, Takashi Ohtani, Tomoko Maeda, Tsugihiko Hidaka
  • Patent number: 10364237
    Abstract: The invention provides tetrahydroquinoline sulfonamide compounds, tetrahydronaphthalene sulfonyl compounds, and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: July 30, 2019
    Assignee: Lycera Corporation
    Inventors: Thomas D. Aicher, Clarke B. Taylor, Chad A. VanHuis
  • Patent number: 10329257
    Abstract: The present invention provides compounds for the treatment of a bacterial infection. Additionally, the present invention provides compositions and methods for using these compounds and compositions in the treatment of a bacterial infection in a subject.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: June 25, 2019
    Assignee: The Broad Institute, Inc.
    Inventors: Michael H. Serrano-Wu, Chao Fang
  • Patent number: 10308620
    Abstract: The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of preparing such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to muscarinic M1 receptor.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: June 4, 2019
    Assignee: SUVEN LIFE SCIENCES LIMITED
    Inventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Anil Karbhari Shinde, Shankar Reddy Gagginapally, Venkateswarlu Jasti
  • Patent number: 10294222
    Abstract: Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: May 21, 2019
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Andrew Felts
  • Patent number: 10266528
    Abstract: The present invention relates to imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: April 23, 2019
    Assignee: Merck Patent GmbH
    Inventor: Richard D. Caldwell
  • Patent number: 10150742
    Abstract: Disclosed herein are pyrimidine compounds of formula I and formula II and methods for treating or preventing a viral infection, such as infections caused by dengue virus in a subject, comprising administering to said subject an effective amount of a pyrimidine compound of formula I or formula II.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 11, 2018
    Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
    Inventors: Priscilla Yang, Nathanael S. Gray, Chandrasekhar Miduturu, Margaret J. Clark
  • Patent number: 10125231
    Abstract: A method of forming carbon-carbon composites includes molding carbon fibers with a compound comprising a blend of benzoxazine resin and cyanate ester resin; and pyrolyzing the compound to form the carbon-carbon composite. A carbon-carbon composite includes carbon fibers impregnated with a compound comprising a blend of benzoxazine resin and cyanate ester.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: November 13, 2018
    Assignee: RAYTHEON COMPANY
    Inventor: Gray E. Fowler
  • Patent number: 10087150
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: October 2, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Takuto Kojima
  • Patent number: 10087169
    Abstract: Compounds and compositions comprising compounds that activate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that activate PKM2 in the treatment of cancer.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: October 2, 2018
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Francesco G. Salituro, Jeffrey O. Saunders
  • Patent number: 10065928
    Abstract: Provided herein are a quinolinone compound, pharmaceutical composition thereof, and use of the compound or the pharmaceutical composition in drug preparation, the drug being used to prevent, manage, treat or relieve diseases related to HIF and/or EPO of a patient, including anemia, vascular disease, myocardial ischemia, dysmetabolism, or for wound healing.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: September 4, 2018
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yinglin Zuo, Xiaojun Wang, Yingjun Zhang, Liang Wen, Shoutao Wu, Xiaofeng Yuan
  • Patent number: 10045985
    Abstract: The present invention relates to pyrimidine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: August 14, 2018
    Assignee: Merck Patent GmbH
    Inventors: Hui Qiu, Richard D. Caldwell, Lesley Liu-Bujalski
  • Patent number: 9988351
    Abstract: A method for producing (2S,5S)/(2R,5R)-5-hydroxypiperidine-2-carboxylic acid represented by the formula (10) below: the method including removing the protecting group from the hydroxyl group in a compound represented by formula (7) below: (wherein P represents a protecting group, R3 represents an alkyl group containing 1 to 4 carbon atoms, and A represents an alkyl group containing 1 to 10 carbon atoms, an aryl group containing 6 to 12 carbon atoms, an alkyloxy group containing 1 to 4 carbon atoms, or an aralkyloxy group containing 7 to 20 carbon atoms) to synthesize a compound represented by formula (8) below: (wherein R3 represents an alkyl group containing 1 to 4 carbon atoms, and A represents an alkyl group containing 1 to 10 carbon atoms, an aryl group containing 6 to 12 carbon atoms, an alkyloxy group containing 1 to 4 carbon atoms, or an aralkyloxy group containing 7 to 20 carbon atoms).
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: June 5, 2018
    Assignee: API CORPORATION
    Inventors: Jun Takehara, Masato Murai, Takashi Ohtani, Tomoko Maeda, Tsugihiko Hidaka
  • Patent number: 9957268
    Abstract: The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: May 1, 2018
    Assignee: Incyte Corporation
    Inventors: Andrew P. Combs, Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh
  • Patent number: 9949976
    Abstract: The invention relates to a CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers; a pharmaceutical formulation, pharmaceutical composition and kit comprising said CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers, and use of said CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers. For example, the compounds of the invention are useful for reducing or inhibiting the activity of CDK4/6 kinase in a cell, and/or treating and/or preventing a cancer-related disease mediated by CDK4/6 kinase.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: April 24, 2018
    Assignees: XUANZHU PHARMA CO., LTD., SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.
    Inventors: Frank Wu, Bo Chen
  • Patent number: 9896441
    Abstract: The invention provides tetrahydroquinoline sulfonamide compounds, tetrahydronaphthalene sulfonyl compounds, and related compounds, pharmaceutical compositions, methods of promoting ROR? activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: February 20, 2018
    Assignee: LYCERA CORPORATION
    Inventors: Thomas D. Aicher, Clarke B. Taylor, Chad A. VanHuis
  • Patent number: 9890154
    Abstract: A series of substituted 3H-imidazo[4,5-c]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: February 13, 2018
    Assignee: UCB Biopharma SPRL
    Inventors: Victoria Elizabeth Jackson, Boris Kroeplien, John Robert Porter
  • Patent number: 9878989
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: January 30, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masataka Murakami, Jinichi Yonemori, Takuto Kojima
  • Patent number: 9822085
    Abstract: A tetrazolinone compound represented by formula (1): [in the formula, R1 represents an alkyl group having 1-6 carbon atoms or the like] can be produced by reacting a compound represented by formula (2): [in the formula, X1 represents a bromine atom or the like, and R1 represents an alkyl group having 1-6 carbon atoms or the like] with a compound represented by formula (A): R—Mg—X??(A) [in the formula, R represents an alkyl group having 1-6 carbon atoms or the like, and X1 represents a bromine atom or the like] to provide a compound represented by formula (3): [in the formula, X2 represents a chlorine atom or the like] and reacting the compound represented by formula (3) with formaldehyde or a compound represented by formula (4): [in the formula, R6 represents an alkyl group having 1-6 carbon atoms or the like, and X3 represents a chlorine atom, bromine atom or iodine atom].
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: November 21, 2017
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Satoru Ujita, Takayuki Shioda
  • Patent number: 9809561
    Abstract: The invention provides certain bicylic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: November 7, 2017
    Assignees: MERCK SHARP & DOHME CORP., LYCERA CORPORATION
    Inventors: Thomas D. Aicher, Chad A. VanHuis, William D. Thomas, John K. MacLean, Brian M. Andresen, Kenneth J. Barr, Corey E. Bienstock, Neville J. Anthony, Matthew Daniels, Kun Liu, Yuan Liu, Catherine M. White, Blair T. Lapointe, Nunzio Sciammetta, Vladimir Simov
  • Patent number: 9783511
    Abstract: The invention provides certain benzoxazine compounds of the Formula (I) or pharmaceutically acceptable salts thereof wherein R1, R2, Ra1, Ra2, Rb1, Rb2, Rc, Rd, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: October 10, 2017
    Assignees: Lycera Corporation, Merck Sharp & Dohme Corp.
    Inventors: Thomas D. Aicher, Chad A. VanHuis, John MacLean, Brian M. Andresen, Kenneth J. Barr, Corey Bienstock, Matthew Daniels, Kun Liu, Yuan Liu, Catherine White, Nunzio Sciammetta, Vladimir Simov
  • Patent number: 9763952
    Abstract: The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R1, R5, R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: September 19, 2017
    Assignee: NOVARTIS AG
    Inventors: Giorgio Caravatti, Sylvie Chamoin, Pascal Furet, Klemens Hogenauer, Konstanze Hurth, Karen Kammertoens, Ian Lewis, Henrik Moebitz, Alexander Baxter Smith, Nicolas Soldermann, Romain Wolf, Frederic Zecri
  • Patent number: 9751846
    Abstract: The present invention provides an industrially advantageous method for producing a 1,4-benzoxazine compound useful as a medicine while avoiding safety and health risks. Specifically, the present invention provides a method for producing a 1,4-benzoxazine compound [A], which comprises the three steps in the following scheme, namely, a step of converting the amino group at 7-position in a compound [a] into a dimesylamino group, a step of coupling a compound [b] with a boronic acid compound, and a step of converting the 7-position in a compound [c] into a monomesylamino group. In the above scheme, Ms is a methanesulfonyl group, and each of R? and R? is a hydrogen atom etc.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: September 5, 2017
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Tomoyuki Okabe, Takeshi Hamada, Kaori Tomikawa, Yukie Okamoto, Toru Iijima, Hidenori Akatsuka, Kenichi Toyama, Atsushi Moroda, Yoshihiro Sugiura
  • Patent number: 9738612
    Abstract: Disclosed are a use of a methylacryloyl benzimidazolone derivative, an optical isomer or a pharmaceutically acceptable salt or prodrug thereof in the preparation of: (a) a pharmaceutical composition or reagent for down-regulating the activity of PI3K/Akt pathways; (b) a pharmaceutical composition or reagent for treating or inhibiting a tumour; and/or inhibiting tumour cell growth; and/or (c) a pharmaceutical composition or reagent for blocking the cell cycle. The compounds involved in the present invention can down-regulate the level of Akt phosphorylation in P13K/Akt signaling pathways, and the functional effects of the compounds are equivalent to those of a novel small-molecular targeting drug MK2206; while the research at the cellular level has found that the methylacryloyl benzimidazolone derivatives represented by FD1 have a good proliferation inhibiting effect on tumour cells. What is different from MK2206 is that FD1 has better effects on a PTEN deleted cell.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: August 22, 2017
    Assignees: Shanghai Nature Standard R&D and Biotech Co., Ltd, Shanghai Standard Technology Co., Ltd., Shanghai Founder Biomed R&D Co., Ltd.
    Inventors: Jiapeng Li, Zhiqin Ji, Xiaoya Zhou, Shaopeng Wei, Yong Qian, Tianpei Xie
  • Patent number: 9695204
    Abstract: The present disclosure provides for processes and intermediates in the large-scale manufacture of the compound of formula (I) or hydrates thereof.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: July 4, 2017
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Benedict McKeever, Louis Joseph Diorazio, Martin Francis Jones, Leigh Ferris, Sophie Laure Marie Janbon, Pawel Stanislaw Siedlecki, Gwydion Huw Churchill, Peter Alan Crafts
  • Patent number: 9598382
    Abstract: A method for producing a purified compound represented by the formula (II), comprising; obtaining a reaction mixture containing a compound represented by the formula (I) from a crude compound represented by the formula (II) such as reacting the crude compound with a ketone compound, and reacting the obtained reaction mixture or a solution by filtering thus obtained reaction mixture containing the compound represented by the formula (I) with water.
    Type: Grant
    Filed: December 25, 2014
    Date of Patent: March 21, 2017
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Tadafumi Matsunaga, Hiromi Kaise
  • Patent number: 9567305
    Abstract: The present invention provides oxazine compounds, method of using and method of making oxazine compounds and its pharmaceutical use.
    Type: Grant
    Filed: January 20, 2014
    Date of Patent: February 14, 2017
    Assignee: Southern Methodist University
    Inventors: Edward R. Biehl, Haribabu Ankati, Sukanta Kamila
  • Patent number: 9539260
    Abstract: The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R1, R5, R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: January 10, 2017
    Assignee: NOVARTIS AG
    Inventors: Giorgio Caravatti, Sylvie Chamoin, Pascal Furet, Klemens Hogenauer, Konstanze Hurth, Karen Kammertoens, Ian Lewis, Henrik Moebitz, Alexander Baxter Smith, Nicolas Soldermann, Romain Wolf, Frederic Zecri
  • Patent number: 9518045
    Abstract: The present invention relates to a process for manufacturing benzoxazinones of formula (I), wherein the variables are defined according to the description, by reacting carbamates of formula (II) are reacted with carbamat-benzoxazinones of formula (III) in the presence of a base.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: December 13, 2016
    Assignee: BASF SE
    Inventors: Maximilian Dochnahl, Roland Goetz, Joachim Gebhardt, Uwe Josef Vogelbacher, Timo Frassetto, Michael Rack, Volker Maywald, Bernd Wolf
  • Patent number: 9456606
    Abstract: The present invention relates to pesticidal mixtures comprising a component A and a component B, wherein component A is a compound of formula (I) wherein B1, B2, B3, X1, X2, X3, X4, Y1, Y2, Y3 and R9 are as defined in claim 1 and component B is an insecticide. The present invention also relates to methods of using said mixtures for the control of plant pests.
    Type: Grant
    Filed: December 12, 2012
    Date of Patent: October 4, 2016
    Assignee: Syngenta Participations AG
    Inventors: Myriem El Qacemi, Jerome Yves Cassayre
  • Patent number: 9446012
    Abstract: This invention relates to novel substituted nitrocatechol derivatives, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: September 20, 2016
    Assignee: BIAL—PORTELA & CA, S.A.
    Inventors: David Alexander Learmonth, Laszlo Erno Kiss, Pedro Nuno Leal Palma, Humberto dos Santos Ferreira, Patricio Manuel V. A. Soares da Silva
  • Patent number: 9409874
    Abstract: The present invention provides an industrially advantageous method for producing a 1,4-benzoxazine compound useful as a medicine while avoiding safety and health risks. Specifically, the present invention provides a method for producing a 1,4-benzoxazine compound [A], which comprises the three steps in the following scheme, namely, a step of converting the amino group at 7-position in a compound [a] into a dimesylamino group, a step of coupling a compound [b] with a boronic acid compound, and a step of converting the 7-position in a compound [c] into a monomesylamino group. In the above scheme, Ms is a methanesulfonyl group, and each of R? and R? is a hydrogen atom etc.
    Type: Grant
    Filed: August 8, 2013
    Date of Patent: August 9, 2016
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Tomoyuki Okabe, Takeshi Hamada, Kaori Tomikawa, Yukie Okamoto, Toru Iijima, Hidenori Akatsuka, Kenichi Toyama, Atsushi Moroda, Yoshihiro Sugiura
  • Patent number: 9409894
    Abstract: The present invention relates to carbamates of formula (I), wherein the variables are defined according to the description, as well as to a process for manufacturing carbamates of formula (I), and to the use of carbamates of formula (I) in manufacturing benzoxazinones of formula (VII).
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: August 9, 2016
    Assignee: BASF SE
    Inventors: Maximilian Dochnahl, Roland Götz, Joachim Gebhardt, Uwe Josef Vogelbacher, Timo Frassetto, Michael Rack, Volker Maywald, Bernd Wolf
  • Patent number: 9394315
    Abstract: The invention provides tetrahydro[1,8]naphthyridine and related compounds, pharmaceutical compositions, methods of promoting ROR? activity, increasing the amount of IL-17 in a subject, and treating cancer, bacterial infections, and fungal infections using such tetrahydro[1,8]naphthyridine and related compounds.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: July 19, 2016
    Assignee: Lycera Corporation
    Inventors: Thomas D. Aicher, Peter L. Toogood, Xiao Hu
  • Patent number: 9388203
    Abstract: The present disclosure provides for processes and intermediates in the large-scale manufacture of the compound of formula (I) or hydrates thereof.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: July 12, 2016
    Inventors: Benedict McKeever, Louis Joseph Diorazio, Martin Francis Jones, Leigh Ferris, Sophie Laure Marie Janbon, Pawel Stanislaw Siedlecki, Gwydion Huw Churchill, Peter Alan Crafts
  • Patent number: 9359312
    Abstract: The present invention relates to a process for manufacturing a benzoxazinone of formula (I), by reacting a nitro compound of formula (II) with a reducing agent to obtain an amino compound of formula (III), and then reacting the amino compound of formula (III) with an acid; wherein the variables are defined according to the description, and benzoxazinone of formula (I).
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: June 7, 2016
    Assignee: BASF SE
    Inventors: Maximilian Dochnahl, Michael Rack, Michael Keil, Bernd Wolf, Uwe Josef Vogelbacher, Joachim Gebhardt, Timo Frassetto, Volker Maywald
  • Patent number: 9353070
    Abstract: The present invention relates to carbamat-benzoxazinones of formula (I), wherein the variables are defined according to the description, as well as to a process for manufacturing carbamat-benzoxazinones of formula (I), and to the use of carbamat-benzoxazinones of formula (I) in manufacturing benzoxazinones of formula (X).
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: May 31, 2016
    Assignee: BASF SE
    Inventors: Maximilian Dochnahl, Roland Goetz, Joachim Gebhardt, Uwe Josef Vogelbacher, Timo Frassetto, Michael Rack, Volker Maywald, Bernd Wolf
  • Patent number: 9346817
    Abstract: Dioxino- and oxazin-[2,3-d]pyrimidine PI3K inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: May 24, 2016
    Assignee: Genentech, Inc.
    Inventors: Robert Andrew Heald, Neville James McLean
  • Patent number: 9307767
    Abstract: Thiazolopyridinones of the general formula (I) are described as herbicides. In this formula (I), R1, R2, R3 and R4 represent radicals such as hydrogen, organic radicals such as alkyl and other radicals such as halogen, nitro and cyano.
    Type: Grant
    Filed: March 25, 2013
    Date of Patent: April 12, 2016
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Christian Waldraff, Stefan Lehr, Alfred Angermann, Hansjoerg Dietrich, Jan Dittgen, Elmar Gatzweiler, Christopher Hugh Rosinger, Angela Becker